Current treatment status-Undergoing active treatment-Progressive despite treatment - Page 16 of 29 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Brentuximab vedotin: a study of its safety for unresponsive Hodgkin lymphoma.

Brentuximab vedotin: a study of its safety for unresponsive Hodgkin lymphoma.

Posted by on Jul 3, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to analyse the side effects associated with brentuximab vedotin (BV; Adcetris) treatment for patients with Hodgkin lymphoma (HL) who had undergone stem cell transplantation (SCT) that is now unresponsive to treatment. The main side effects identified included nerve damage, infections and low white blood cell...

Read More

Is busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?

Is busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?

Posted by on Jun 26, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of using busulfan to delete blood cancer cells from the system before replacing them with normal cells in the treatment of leukaemia. The study found that busulfan therapy was effective in removing blood cancer cells before replacement, in the treatment of high-risk acute leukaemia. Some background Acute...

Read More

What are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?

What are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?

Posted by on Jun 19, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?

Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?

Posted by on May 31, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...

Read More

What type of stem cell transplant is most effective after early treatment failure in follicular lymphoma?

Posted by on May 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of stem cell transplantation in follicular lymphoma patients who experienced early treatment failure after frontline chemoimmunotherapy. This study concluded that transplants using the patient's own stem cells or those from a matched sibling donor lead to better survival outcomes in these...

Read More

Radiotherapy for relapsed or refractory diffuse large b-cell lymphoma

Radiotherapy for relapsed or refractory diffuse large b-cell lymphoma

Posted by on May 29, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More